Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review.

Journal of cancer research and clinical oncology - 1 Jul 2023

Sheth Hardik, Limaye Sewanti, Kumar Prashant, Shreenivas Aditya

Abstract excerpt

PURPOSE: Advanced gall bladder cancer (GBC) is an aggressive disease, and there is no consensus on treatment options beyond first-line chemotherapy. We report a case of an elderly male with FGFR2-altered advanced adenocarcinoma of the gallbladder who failed two prior lines of chemotherapy but had sustained response and stable disease on sequential FGFR-directed targeted therapy. DESIGN: We describe a case of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged
Share to Gallbladder Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Identifiers

PMID: 36307559
DOI: 10.1007/s00432-022-04428-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review.PMID 36307559Read ↗

Sustained Response on Sequential Anti-fgfr Therapy in Metastatic Gall Bladder Cancer - a Case Report and Literature ReviewSemantic proximity Read ↗

A case of advanced biliary tract cancer with EGFR amplification that responded to Necitumumab and post-treatment resistance changes detected by liquid biopsySemantic proximity Read ↗

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.Semantic proximity Read ↗

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity Read ↗

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Semantic proximity Read ↗

FGFR2 Inhibition in Cholangiocarcinoma.Semantic proximity Read ↗

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.Semantic proximity Read ↗

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.Semantic proximity Read ↗

Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practiceSemantic proximity Read ↗

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmSemantic proximity Read ↗

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Semantic proximity Read ↗

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.